ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1225

Nailfold Video Capillaroscopy and Its Association with Autoantibodies and Rheumatic Diseases in Pediatric Patients
Abstract Number: 0300

Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathy Compared with Healthy Controls
Abstract Number: 0994

Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias
Abstract Number: 1947

National Incidence, Prevalence & Mortality in Idiopathic Inflammatory Myopathies & Associated Interstitial Lung Disease in England
Abstract Number: 1143

Nationwide Analysis of Adult-Onset Still’s Disease with and Without Hemophagocytic Lymphohistiocytosis
Abstract Number: 1918

Nationwide Analysis of Predictors of Sarcoid Inpatient Mortality
Abstract Number: 1278

Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability
Abstract Number: 2069

Navigating the Residency-to-Fellowship Transition in Rheumatology
Abstract Number: 0351

Needs Assessment Survey of Critical Data Element Completion in Telemedicine Visits for Juvenile Idiopathic Arthritis in the Post-Pandemic Period
Abstract Number: 0629

Negative Affect, Anxiety and Fatigue Moderate the Association Between Pain Intensity and Physical Function in People with Systemic Sclerosis
Abstract Number: 0886

Neonatal Roseolovirus Infection Predisposes to Development of Lupus-like Disease After TLR7 Stimulation
Abstract Number: 1261

Network Analysis of Depression and Anxiety Symptoms in Chinese Rheumatoid Arthritis Patients
Abstract Number: 0918

Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 0971

Network Meta Analyses of the Effectiveness and Safety Profiles of Janus Kinase Inhibitors and Biologic Agents in Treating Children with Non-systemic Juvenile Idiopathic Arthritis (nsJIA)
Abstract Number: 1541

Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].